

FY2021 IPPS Final Rule New Technology Add-on Payment for Drugs Summary

Drug-Generic	Drug-Brand	Newness Start Date	FDA Approval Date for NTAP indication	FY2021 IPPS NTAP Status	HCPCS Effective 10/01/2020	FY2021 Max Payment	FY2021 ICD-10-PCS Codes
Tisagenlecleucel (CAR T-cell)	Kymriah	11/22/2017	05/2018	Discontinue	Q2042	N/A	N/A
Axicabtagene ciloleucel (CAR T-cell)	Yescarta	11/22/2017	10/2017	Discontinue	Q2041	N/A	N/A
Daunorubicin/Cytarabine	Vyxeos	8/3/2017	08/2017	Discontinue	J9153	N/A	N/A
Meropenem/Vaborbactam	Vabomere	8/29/2017	08/2017	Discontinue	J2186	N/A	N/A
Plazomicin	Zemdri	6/25/2018	06/2018	Continue	J0291	\$4,083.75	XW033G4, XW043G4
Synthetic Human Angiotensin II	Giapreza	12/21/2017	12/2017	Discontinue	C9399	N/A	N/A
Andexanet alfa	Andexxa	5/3/2018	05/2018	Continue	J7169*	\$18,281.25	XW03372, XW04372
Ultratrace iobenguane Iodine-131	Azedra	7/30/2018	07/2018	Continue	A9590*	\$98,150.00	XW033S5, XW043S5
Caplacizumab-yhdp	Cablivi	2/6/2019	02/2019	Continue	C9047	\$33,215.00	XW013W5, XW033W5, XW043W5
Tagraxofusp-erzs	Elzonris	12/21/2018	12/2018	Continue	J9269	\$125,448.05	XW033Q5, XW043Q5
Erdafitinib (PO chemotherapy)	Balversa	4/12/2019	04/2019	Continue	C9399 or J8999	\$3,563.23	XW0DXL5
Apalutamide (PO chemotherapy)	Erleada	2/14/2018	02/2018	Discontinue	C9399 or J8999	N/A	N/A
Esketamine (Nasal)	Spravato	3/5/2019	03/2019	Continue	C9399 or J3490	\$1,014.79	3E097GC, Effective: 10/1/2020: XW097M5
Gilteritinib (PO chemotherapy)	Xospata	11/28/2018	11/2018	Continue	C9399 or J8999	\$7,312.50	XW0DXV5
Ruxolitinib (PO)	Jakafi	5/24/2019	05/2019	Continue	C9399 or J8499	\$4,096.21	XW0DXT5
Durvalumab	Imfinzi	3/18/2019	3/2020	New Tech	J9173	\$6,875.90	XW03336, XW04336
Atezolizumab	Tecentriq	3/18/2019	3/2019	New Tech	J9022	\$6,875.90	XW033D6, XW043D6
Eculizumab	Soliris	6/27/2019	6/2019	New Tech	J1300	\$21,199.75	XW033C6, XW043C6
Brexanolone	Zulresso	6/17/2019	3/2019	Denied	N/A	N/A	N/A
Cefiderocol	Fetroja	2/24/2020	11/2019	New QIDP	C9399	\$7,919.86	XW033A6, XW043A6
Fosfomycin	Contepo	TBD		Must meet marketing by	C9399	\$2,343.75	XW033K5, XW043K5
Omadacycline	Nuzyra	2/1/2019	10/2018	New Tech/QIDP	J0121	\$1,552.50	XW033B6, XW043B6
Imipenem/Cilastatin/relebactam	Recarbrio	1/6/2020	7/2019	New Tech/QIDP	J0742	\$3,532.78	XW033U5, XW043U5
Lefamulin	Xenleta	9/10/2019	8/2019	New Tech/QIDP	J0691	\$1,275.75	XW03366, XW04366,
Ceftolozane/tazobactam	Zerbaxa	6/3/2019	6/2019	New Tech/QIDP	J0695	\$1,836.98	XW03396, XW04396

*Indicates HCPCS has changed within the previous year

Updated: 9/21/2020

Disclaimer:

The Pharmacy Revenue Cycle internet web site provides "hyperlinks" to other internet web sites that contain information created, published, maintained or otherwise posted by institutions or organizations independent of the developers of the Pharmacy Revenue Cycle website. We do not endorse, approve, certify or control those external web sites, and we do not guarantee the accuracy, completeness, efficacy or timeliness of information located at those sites. Use of any information obtained from those web sites is voluntary, and reliance on that information should only be undertaken after an independent review of its accuracy. "Tools" are posted as pdf files with a date stamp to preserve the time-sensitivity of the external information that was used to develop the tool. Use of our "Tools" is voluntary and the information should be independently reviewed for accuracy and applicability to your situation.

FY2021 IPPS Final Rule New Technology Add-on Payment for Drugs Summary

Drug-Generic	ICD-10-PCS Effective Date	ICD -10-PCS Code	Description
Plazomicin	10/1/2018	XW033G4	Introduction of Plazomicin anti-infective into peripheral vein, percutaneous approach, new technology group 4
	10/1/2018	XW043G4	Introduction of Plazomicin anti-infective into central vein, percutaneous approach, new technology group 4
Andexanet alfa	10/1/2019	XW03372	Introduction of Andexanet alfa, Factor Xa inhibitor reversal agent into peripheral vein, percutaneous approach, new technology group 2
	10/1/2019	XW04372	Introduction of Andexanet alfa, Factor Xa inhibitor reversal agent into central vein, percutaneous approach, new technology group 2
Ultratrace iobenguane Iodine-131	10/1/2019	XW03355	Introduction of Iobenguane I-131 Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 5
	10/1/2019	XW04355	Introduction of Iobenguane I-131 Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 5
Caplacizumab-yhdp	10/1/2019	XW013W5	Introduction of Caplacizumab into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 5
	10/1/2019	XW033W5	Introduction of Caplacizumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5
	10/1/2019	XW043W5	Introduction of Caplacizumab into Central Vein, Percutaneous Approach, New Technology Group 5
Tagraxofusp-erzs	10/1/2019	XW033Q5	Introduction of Tagraxofusp-erzs Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 5
	10/1/2019	XW043Q5	Introduction of Tagraxofusp-erzs Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 5
Erdafitinib	10/1/2019	XW0DXL5	Introduction of Erdafitinib Antineoplastic into Mouth and Pharynx, External Approach, New Technology Group 5
Esketamine	10/1/2015	3E097GC	Introduction of Other Therapeutic Substance into Nose, Via Natural or Artificial Opening
Esketamine	10/1/2020	XW097M5	Introduction of Esketamine Hydrochloride into nose, via natural or artificial opening, new technology group 5
Gilteritinib	10/1/2019	XW0DXV5	Introduction of Gilteritinib Antineoplastic into Mouth and Pharynx, External Approach, New Technology Group 5
Ruxolitinib	10/1/2019	XW0DXT5	Introduction of Ruxolitinib into Mouth and Pharynx, External Approach, New Technology Group 5
Fosfomycin	10/1/2019	XW033K5	Introduction of Fosfomycin Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 5
	10/1/2019	XW043K5	Introduction of Fosfomycin Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 5
Durvalumab	10/1/2020	XW03336	Introduction of durvalumab antineoplastic into peripheral vein, percutaneous approach, new technology group 6
	10/1/2020	XW04336	Introduction of durvalumab antineoplastic into central vein, percutaneous approach, new technology group 6
Atezolizumab	10/1/2020	XW033D6	Introduction of atezolizumab antineoplastic into peripheral vein, percutaneous approach, new technology group 6
	10/1/2020	XW043D6	Introduction of atezolizumab antineoplastic into central vein, percutaneous approach, new technology group 6
Eculizumab	10/1/2020	XW033C6	Introduction of eculizumab into peripheral vein, percutaneous approach, new technology group 6
	10/1/2020	XW043C6	Introduction of eculizumab into central vein, percutaneous approach, new technology group 6
Cefiderocol	10/1/2020	XW033A6	Introduction of cefiderocol into peripheral vein, percutaneous approach, new technology group 6
	10/1/2020	XW034A6	Introduction of cefiderocol into central vein, percutaneous approach, new technology group 6
Omadacycline	10/1/2020	XW033B6	Introduction of omadacycline anti-infective into peripheral vein, percutaneous approach, new technology group 6
	10/1/2020	XW043B6	Introduction of omadacycline anti-infective into peripheral vein, percutaneous approach, new technology group 6
Imipenem/Cilastatin/relebactam	10/1/2019	XW033U5	Introduction of imipenem-cilastatin-relebactam anti-infective into peripheral vein, percutaneous approach, new technology group 5
	10/1/2019	XW043U5	Introduction of imipenem-cilastatin-relebactam anti-infective into central vein, percutaneous approach, new technology group 5
Lefamulin	10/1/2020	XW03366	Introduction of lefamulin anti-infective into peripheral vein, percutaneous approach, new technology group 6
	10/1/2020	XW04366	Introduction of lefamulin anti-infective into central vein, percutaneous approach, new technology group 6
	10/1/2020	XW0DX66	Introduction of lefamulin anti-infective into mouth and pharynx, external approach, new technology group 6
Ceftolozane/tazobactam	10/1/2020	XW03396	Introduction of Ceftolozane/Tazobactam Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 6
	10/1/2020	XW04396	Introduction of Ceftolozane/Tazobactam Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 6

Disclaimer:

The Pharmacy Revenue Cycle internet web site provides "hyperlinks" to other internet web sites that contain information created, published, maintained or otherwise posted by institutions or organizations independent of the developers of the Pharmacy Revenue Cycle website. We do not endorse, approve, certify or control those external web sites, and we do not guarantee the accuracy, completeness, efficacy or timeliness of information located at those sites. Use of any information obtained from those web sites is voluntary, and reliance on that information should only be undertaken after an independent review of its accuracy. "Tools" are posted as pdf files with a date stamp to preserve the time-sensitivity of the external information that was used to develop the tool. Use of our "Tools" is voluntary and the information should be independently reviewed for accuracy and applicability to your situation.